| Ada Ivette Mercado, MD | |
|
687 Marietta Hwy, Canton, GA 30114-2608 | |
| (770) 704-1955 | |
| (770) 720-2388 |
| Full Name | Ada Ivette Mercado |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 34 Years |
| Location | 687 Marietta Hwy, Canton, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982620811 | NPI | - | NPPES |
| 000967029K | Medicaid | GA | |
| 000967029M | Medicaid | GA | |
| 000967029I | Medicaid | GA | |
| 000967029L | Medicaid | GA | |
| 000967029G | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 51357 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellstar Kennestone Hospital | Marietta, GA | Hospital |
| Wellstar North Fulton Hospital | Roswell, GA | Hospital |
| Wellstar Cobb Hospital | Austell, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellstar Medical Group, Llc | 6709065402 | 1839 |
News Archive
Boston scientists have found a hormone that is secreted by muscles during exercise and boosts the amount of energy the body burns. This hormone – irisin – could be the first step in development of new drugs for obesity, diabetes, and other diseases feel researchers. A Boston startup company, Ember Therapeutics, has already licensed the technology and is working to develop a form of the hormone that could be used as a drug that would mimic some of the benefits of exercise.
CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.
A clinical research study published in the British Journal of Surgery shows that fluorescence guidance (where a fluorescent chemical compound re-emits light with a long wavelength) can enable a colorectal surgeon to assess cancer tissues visually and with more specificity in real-time during surgery, by utilising near-infrared (NIR) light from an administered fluorophore in conjunction with artificial intelligence (AI) methods.
University of Louisville researchers are one step closer to helping millions of people whose salivary glands no longer work because of disease or damage from treatment of diseases.
BioSante Pharmaceuticals, Inc. today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions.
› Verified 2 days ago
| Entity Name | North Atlanta Professional Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316959869 PECOS PAC ID: 0840291944 Enrollment ID: O20070116000197 |
News Archive
Boston scientists have found a hormone that is secreted by muscles during exercise and boosts the amount of energy the body burns. This hormone – irisin – could be the first step in development of new drugs for obesity, diabetes, and other diseases feel researchers. A Boston startup company, Ember Therapeutics, has already licensed the technology and is working to develop a form of the hormone that could be used as a drug that would mimic some of the benefits of exercise.
CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.
A clinical research study published in the British Journal of Surgery shows that fluorescence guidance (where a fluorescent chemical compound re-emits light with a long wavelength) can enable a colorectal surgeon to assess cancer tissues visually and with more specificity in real-time during surgery, by utilising near-infrared (NIR) light from an administered fluorophore in conjunction with artificial intelligence (AI) methods.
University of Louisville researchers are one step closer to helping millions of people whose salivary glands no longer work because of disease or damage from treatment of diseases.
BioSante Pharmaceuticals, Inc. today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions.
› Verified 2 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
Boston scientists have found a hormone that is secreted by muscles during exercise and boosts the amount of energy the body burns. This hormone – irisin – could be the first step in development of new drugs for obesity, diabetes, and other diseases feel researchers. A Boston startup company, Ember Therapeutics, has already licensed the technology and is working to develop a form of the hormone that could be used as a drug that would mimic some of the benefits of exercise.
CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.
A clinical research study published in the British Journal of Surgery shows that fluorescence guidance (where a fluorescent chemical compound re-emits light with a long wavelength) can enable a colorectal surgeon to assess cancer tissues visually and with more specificity in real-time during surgery, by utilising near-infrared (NIR) light from an administered fluorophore in conjunction with artificial intelligence (AI) methods.
University of Louisville researchers are one step closer to helping millions of people whose salivary glands no longer work because of disease or damage from treatment of diseases.
BioSante Pharmaceuticals, Inc. today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ada Ivette Mercado, MD 55 Whitcher St Ne, Suite 350, Marietta, GA 30060-1155 Ph: (770) 424-6893 | Ada Ivette Mercado, MD 687 Marietta Hwy, Canton, GA 30114-2608 Ph: (770) 704-1955 |
News Archive
Boston scientists have found a hormone that is secreted by muscles during exercise and boosts the amount of energy the body burns. This hormone – irisin – could be the first step in development of new drugs for obesity, diabetes, and other diseases feel researchers. A Boston startup company, Ember Therapeutics, has already licensed the technology and is working to develop a form of the hormone that could be used as a drug that would mimic some of the benefits of exercise.
CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.
A clinical research study published in the British Journal of Surgery shows that fluorescence guidance (where a fluorescent chemical compound re-emits light with a long wavelength) can enable a colorectal surgeon to assess cancer tissues visually and with more specificity in real-time during surgery, by utilising near-infrared (NIR) light from an administered fluorophore in conjunction with artificial intelligence (AI) methods.
University of Louisville researchers are one step closer to helping millions of people whose salivary glands no longer work because of disease or damage from treatment of diseases.
BioSante Pharmaceuticals, Inc. today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions.
› Verified 2 days ago
Priti V Jindal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 240 Marietta Hwy, Canton, GA 30114 Phone: 812-360-3381 Fax: 812-269-5214 | |
Craig Neale Rosebrock, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 201 Hospital Rd, Appartment Uu1, Canton, GA 30114 Phone: 770-720-6325 Fax: 404-851-6325 | |
Stacy Ann Cartmell, Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 450 Northside Cherokee Blvd, Canton, GA 30115 Phone: 770-224-1000 | |
Varsha Nirav Patel, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 450 Northside Cherokee Blvd, Canton, GA 30115 Phone: 770-224-1000 Fax: 770-224-2451 | |
Joshua Paul Myers, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 450 Northside Cherokee Blvd, Canton, GA 30115 Phone: 770-224-1000 Fax: 770-224-2451 | |
Christina Powers, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 470 Northside Cherokee Blvd, Ste 380, Canton, GA 30115 Phone: 770-721-9250 Fax: 770-721-9251 | |
Dr. Robert Lee Allen, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 450 Northside Cherokee Blvd, Canton, GA 30115 Phone: 770-224-1000 Fax: 770-224-2451 |